Dec 17, 2021 / 10:30PM GMT
Operator
Good evening. My name is Brent, and I will be your conference operator today. At this time, I would like to welcome everyone to the call. (Operator Instructions) I'd like to introduce Beth DelGiacco, Vice President of Corporate Communications and Investor Relations. You may begin your conference.
Beth DelGiacco - argenx SE - VP of IR
Thank you, Brent. We're very excited to be here today to discuss the FDA approval of efgartigimod, now with the easier to pronounce brand name VYVGART. The press release and corresponding presentation can be found on our website at argenx.com/investors.
Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development, regulatory timelines, the potential success of our product candidates, the market for and market acceptance of our products, financial projections and upcoming milestones. Actual results may differ materially from those indicated by these statements. Argenx is not under any
argenx SE To Discuss FDA Approval Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers